SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals...
Hence then, the article about xellsmart secures fda clearance for three phase i inds of allogeneic ipsc derived cell therapies targeting major cns diseases parkinson s diseases spinal cord injury and als was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS )
Also on site :
- BTS’ j-hope Joins Forces With Streetwear Legend Nigo for New Nike Sneakers: How to Shop the Drop
- Gypsy-Rose Blanchard served years in prison for her mother’s 2015 murder; her memoir is now a No. 1 bestseller
- Meta’s revenue surges to $64.6 billion, but billions in settlements and skyrocketing AI spending turn screws on profit, free cash flow